Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1920-1927

  Hsu, Yao Chun ^a,b   Wu, Chun Ying ^a,c,d   Lane, Hsien Yuan ^a   Chang, Chi Yang ^b   Tai, Chi Ming ^b   Tseng, Cheng Hao ^b   Lo, Gin Ho ^b   Perng, Daw Shyong ^b   Lin, Jaw Town ^e   Mo, Lein Ray ^b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Antiviral therapy; Diabetes mellitus; Hepatitis B virus; Liver cirrhosis; Risk stratification

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; METFORMIN; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; NUCLEOSIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CARCINOMA; CHRONIC HEPATITIS; COHORT ANALYSIS; DIABETES MELLITUS; ECHOGRAPHY; ENDOSCOPY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; INCIDENCE; MIDDLE AGED; MORTALITY; RISK FACTOR; SURVIVAL;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NUCLEOSIDES; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84902438276     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku041     Document Type: Article

References (34)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
3. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Tseng TC, Liu CJ, Yang HC et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.e3; quiz e13-4.
5. Osborn MK, Lok AS. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006; 57: 1030-4.
6. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
7. Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
8. Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
9. Wu CY, Chen YJ, Ho HJ et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-14.
10. Hosaka T, Suzuki F, Kobayashi M et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
11. Sherman M. Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma? Hepatology 2013; 58: 18-20.
12. Hung CH, Lu SN, Wang JH et al. Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003; 38: 153-7.
13. Poon D, Anderson BO, Chen LT et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-8.
14. Lin CW, Lin CC, Mo LR et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol 2013; 58: 730-5.
15. Malinchoc M, Kamath PS, Gordon FD et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
16. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
17. Yang HI, Yuen MF, Chan HL et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-74.
18. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-54.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496-509.
20. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-8.
21. Wong VW, Chan SL, Mo F et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-5.
22. Asahina Y, Tsuchiya K, Nishimura T et al. a-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253-62.
23. Wong GL, Chan HL, Tse YK et al. On-treatment a-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014; doi:10.1002/ hep.26739.
24. Li Z, Tuteja G, Schug J et al. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148: 72-83.
25. Ma WL, Hsu CL, Wu MH et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008; 135: 947-955.e5.
26. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.
27. Chen CL, Yang HI, Yang WS et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-21.
28. Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011; 15: 281-96, vii-x.
29. Singh S, Singh PP, Singh AG et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-91; quiz 892.
30. Chen HP, Shieh JJ, Chang CC et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-15.
31. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143-56.
32. Hsu YC, Ho HJ, Wu MS et al. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 2013; 58: 150-7.
33. Huo TI, Wu JC, Lin RY et al. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J Gastroenterol Hepatol 1997; 12: 747-51.
34. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int 2011; 31: 7-21.